Sorry, you need to enable JavaScript to visit this website.

Patient Support & Access | XARELTO® (rivaroxaban) HCP


Covered at the preferred brand tier for more* patients than any other DOAC1


Do your patients pay more than $85 monthly out of pocket for their prescription of XARELTO®? Janssen Select may be able to help.

If your patients pay more than $85 for a 30-day XARELTO® prescription, click below.

Patients can register for


At Janssen, we know that it can be hard for your patients to stay on treatment when their out-of-pocket costs increase during a coverage gap (eg, commercial high deductibles or the Medicare Part D coverage gap, formerly known as the “Donut Hole"). That’s why we created Janssen Select.

Through Janssen Select your patients can:

  • Pay $85, plus sales tax if applicable, for a 30-day (1-month) supply of XARELTO®.
  • Or, pay $240 for a 90-day (3-month) supply of XARELTO® ($80 per month), plus sales tax if applicable, if the patient and provider choose a 90-day supply.
  • Have the same XARELTO® they’d expect delivered directly to their door by Wegmans pharmacy.
  • Participate without paying a membership fee or sharing their income information. This program can even help people who may not have qualified for affordability support in the past.
  • Register beginning April 1 and get refills until December 31, and they can discontinue anytime.

Terms expire at the end of each calendar year and may change.

To register, patients must have insurance covering a portion of the cost of XARELTO® and are being asked to pay more than $85 monthly for XARELTO® through their insurance. Terms expire at the end of each calendar year and may change.

Patients can learn more about the program requirements and register at

For more information, patients can call 888-XARELTO (888-927-3586), Monday-Friday, 8:00 AM-8:00 PM ET.


Savings Program for eligible commercially insured patients

Provider Portal


  • Benefits investigations & prior authorizations
  • Enroll eligible patients in Savings Program
  • View Savings Program transactions

Your patients could be eligible to pay $10 per fill with the Janssen CarePath Savings Program for XARELTO®
  • Eligible patients using commercial or private insurance can save on out-of-pocket costs for XARELTO®. Depending on the health insurance plan, savings may apply toward co-pay, co-insurance, or deductible
  • Eligible commercial patients pay $10 for each 30-day to 90-day prescription for XARELTO®, subject to program benefit limits. There is no limit to this benefit for the first 90 days, and then a $200 limit for each 30-day supply thereafter. There is a $3,400 maximum program benefit per calendar year
  • Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Patients prescribed XARELTO® 10 mg because of a recent non-surgical hospital discharge or because they have recently undergone hip or knee replacement surgery are not eligible. Terms expire at the end of each calendar year and may change. There is no income requirement
  • When patients register, they'll receive a Janssen CarePath Savings Program card. They can download, print, and present the card at their pharmacy along with a valid prescription. Their eligibility to use this card is dependent upon meeting the program requirements each time they present the card when filling their prescription

If you have any questions, please call a Janssen CarePath Care Coordinator at 877-CarePath (877-227-3728), Monday-Friday, 8:00 AM-8:00 PM ET. Multilingual phone support is available.

See full eligibility requirements.

Other Ways to Save on XARELTO® Costs

If your patients aren’t eligible for the Janssen CarePath Savings Program or Janssen Select, we can provide information on other resources that may help them save on XARELTO®.

Visit for information on affordability programs and independent foundations that may have funding available to help them with medication costs for XARELTO®.


Janssen is dedicated to making XARELTO® affordable and accessible for all patients. XARELTO® is widely accessible nationwide with preferred coverage for ~95%§ of commercial and >95% of Medicare Part D patients.1

To see the formulary coverage for your patients, enter your ZIP code. Your results will appear below.

Collected in 04/23 and may change.

This percentage may not represent 100% of formulary lives due to data limitations.

This information is not a promise of coverage or payment. It is not intended to give reimbursement advice or increase reimbursement by any payer. Legal requirements and plan information can be updated frequently. Contact the plan for more information about current coverage, reimbursement policies, restrictions, or requirements that may apply.

Please see below for details regarding references and footnotes.



  • Provides information on affordability options including information about independent foundations that may have available funding to help minimize drug costs for XARELTO®

For more information, visit Janssen Prescription Assistance.

Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF)

The Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is an independent, nonprofit organization. JJPAF gives eligible patients free prescription medicines donated by Johnson & Johnson companies. Patients may be eligible if they don’t have insurance, if their medicine is not covered by insurance, or if they have Medicare coverage and can’t pay for their medicine.
Do you have patients who may need help? They can see if they are eligible and get an application at or call 800-652-6227 (Monday through Friday, 9:00 AM to 6:00 PM ET).

*“More” refers to an absolute difference greater than or equal to ±5%.

Fill medication up to 90 days.

Independent co-pay assistance foundations have their own rules for eligibility. We cannot guarantee a foundation will help your patients. We only can refer you to a foundation that supports their disease state. This information is provided as a resource for you. We do not endorse any particular foundation.

§Within 2% of the access being stated.

llPrior Authorization (PA) and/or Step Therapy (ST): This plan requires the physician to gain prior approval for use of this product, and/or requires the patient to step through and fail an alternate product before this product is dispensed.

Reference: 1: Source: Managed Markets Insight and Technology, LLC, a trademark of MMIT, as of April 03, 2023.

DOAC=direct oral anticoagulant.